A health worker administers Covishield, Serum Institute of India's version of the AstraZeneca vaccine, during a drive-in vaccination program in Kolkata, India, Wednesday, June 16, 2021. (Photo: AP)
NEW DELHI, June 17 (Xinhua) -- Head of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI), Dr N K Arora said Biological E's made-in-India vaccine is expected to have 90 percent effectiveness against COVID-19 and will likely be a gamechanger in the fight against the pandemic.
Arora in an interview to a local television news channel NDTV Thursday said the vaccine is entering Phase 3 trials and could be available by October.
According to Arora, Biological E's vaccine -- to be called Corbevax -- is similar to the Novavax vaccine.
Biological E will be out likely in October with an efficacy matching Novavax's.
India started the vaccination against COVID-19 on January 16 by administrating two made-in-India vaccines -- Covishield and Covaxin.
Of late Russian COVID-19 vaccine -- Sputnik V too was rolled out in the country.
